The Food and Drug Administration (FDA) has recently released a memo indicating that six lots of Doxycycline Hyclate 100-mg tablets manufactured by West-Ward Pharmaceuticals may be used beyond their labeled expiration dates assuming they were stored under the manufacturer’s labeled storage conditions. FDA is not requiring that these products be relabeled but stakeholders who dispense these medication during an actual public health emergency response should inform the receipts that FDA has determined that the product may be safely and effectively used beyond its labeled expiration date.

The FDA is not testing additional lots of doxycycline products outside of the Department of Defense / FDA Shelf-Life Extension Program or accepting requests from states and locals at this time for testing of additional lots of doxycycline or other products. However, medical countermeasures (MCMs) in state and local caches should continued to be stored according to manufacturer specified conditions until either further information is provided or the jurisdiction opts to properly dispose of the products.

For questions related to this memorandum, please contact Brad Leissa at [email protected] or Brooke Courtney at [email protected].

To view the entire memo for additional details and to see which doxycycline lots are affected, click here.

To learn more about other previously released FDA statements on MCMs, click here.